Table 1 Basic characteristics of the studies included in this meta-analysis
Author | Study ID | Country | Number | Regimens(number of arm) | Primary Endpoint | Second Endpoint | Gender M/F (IP VS EP) | Average Age (year) | PS (0–1)% (IP VS EP) |
|---|---|---|---|---|---|---|---|---|---|
Kim et al | 2018 | Korea | 362 | IP: irinotecan 65 mg/m2 d1,8 cisplatin 70 mg/m2 d1(30) EP: etoposide 100 mg/m2 d1–3 cisplatin 70 mg/m2 d1(32) | OS | Toxicity、PFS、ORR、 CR、PR, etc | 151/22 177/12 | 66 65 | 85.5 84.6 |
Y.Shi et al | 2015 | China | 62 | IP: irinotecan 65 mg/m2 d1,8 cisplatin 75 mg/m2 d1(30) EP: etoposide 100 mg/m2 d1–3 cisplatin 75 mg/m2 d1(32) | PFS | ORR、OS and toxicity | 22/9 26/6 | 59 57 | 90 90.7 |
A.Schmittel et al | 2011 | German | 216 | IP: irinotecan 50 mg/m2 d1,8,15 carboplatin AUC 5 mg.min/ml(106) EP: etoposide 140 mg/m2 d1–3 carboplatin AUC 5 mg.min/ml(110) | PFS | OS、response rate and toxicity | 70/36 71/39 | 60 63 | 80 80 |
P. Zatloukal et al | 2010 | predominantly European countries | 405 | IP: irinotecan 65 mg/m2 d1,8 cisplatin 80 mg/m2 d1(202) EP: etoposide 100 mg/m2 d1–3 cisplatin 80 mg/m2 d1(203) | OS | ORR、the duration of Response, etc | 154/48 155/48 | 59 60 | 99 100 |
Lara et al | 2009 | American | 651 | IP: irinotecan 60 mg/m2 d1,8,15 cisplatin 60 mg/m2 d1(324) EP: etoposide 100 mg/m2 d1–3 cisplatin 80 mg/m2 d1(327) | Not State | Not State | 188/136 182/145 | 62 63 | 100 100 |
Hermes et al | 2008 | Norway and Sweden | 209 | IC: irinotecan 175 mg/m2 d1 carboplatin AUC 4 mg.min/ml d1(105) EC: etoposide 120 mg/m2(orally) d1–5 carboplatin AUC 4 mg.min/ml d1(104) | OS | quality of life、CR | 66/39 72/32 | 67 68 | 53 52 |
Pan et al | 2006 | China | 61 | IP: irinotecan 80 mg/ m2 d1,8,15 cisplatin 80 mg/ m2 d1–3(30) EP: etoposide 120 mg/ m2 d1–3 cisplatin 80 mg/ m2 d1–3(31) | Not State | Not State | 24/6 23/8 | 54 51 | 100 100 |
Hanna et al | 2006 | American | 331 | IP: irinotecan 65 mg/m2 d1,8 cisplatin 30 mg/m2(221) EP: etoposide 120 mg/m2 d1–3 cisplatin 60 mg/m2(110) | OS | response rate、TTP | 127/94 63/47 | 63 62 | 92.3 88.2 |
Noda et al | 2002 | Japan | 154 | IP: irinotecan 60 mg/m2 d1,8,15 cisplatin 60 mg/m2 d1(77) EP: etoposide 100 mg/m2 d1–3 cisplatin 80 mg/m2 d1(77) | OS | CR、ORR、PFS, etc | 63/14 69/8 | 63 63 | 92 87 |